Larimar Therapeutics, Inc. LRMR 深 沪
交易中 03-25 11:44:46 美东时间
4.70
+0.130
+2.84%
华盛通- 最 高4.75
- 今 开4.61
- 成交量 315.98万股
- 最 低 4.57
- 昨 收 4.57
- 总市值 4.87亿
- 52周最高 6.42
- 市盈率 静 --
- 换手率 3.05%
- 52周最低 1.61
- 委 比 61.54%
- 总股本 1.04亿
- 历史最高 664.32
- 量 比 5.04
- 振 幅 3.94%
- 历史最低 1.53
- 每 手 1
- 风险率 0.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22
Larimar Therapeutics press release (LRMR): Q4 GAAP EPS of -$0.73 misses by $0.22. $244.5 million in pro forma cash, cash equivalents and marketable securities as of December 31, 2025, with projected c...
03-19 19:21
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.45) by 62.22 percent. This is a 62.22 percent decrease over losses of $(0.45) per share
03-19 19:08
Larimar Therapeutics Q4 net loss widens on higher R&D costs
Larimar Therapeutics Q4 net loss widens on higher R&D costs Overview US biotech firm's Q4 net loss widened, driven by higher R&D expenses for nomlabofusp Company completed $115 mln public offering in Feb 2026, extending cash runway into Q2 2027 FDA granted Breakthrough Therapy Designation for nomlab
03-19 19:08
Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million
Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million Larimar published a fourth-quarter and full-year 2025 financial results press release. Q4 net loss widened 117% to USD 62.5 million, while R&D expense rose 122% to
03-19 19:05
BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million
BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million Mar 19 (Reuters) - Larimar Therapeutics Q4 income from operations USD -64.018 million. Q4 operating expenses USD 64.018 million Q4 EPS USD -0.73
03-19 19:00
Larimar Advances Nomlabofusp Toward 2026 BLA Submission
Larimar Therapeutics ( ($LRMR) ) has issued an update. On March 9, 2026, Larima...
03-10 04:33
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Larimar Therapeutics announced that its management team will present and participate in 1x1 investor meetings at two upcoming conferences in Miami Beach, FL: the Leerink Partners Global Healthcare Conference on March 10, 2026, and The Citizens Life Sciences Conference on March 11, 2026. Details and webcast links are available on the company's website. Larimar focuses on developing treatments for complex rare diseases, with its lead compound, noml...
03-04 21:05
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
